Matthew Gumbleton
( out of 14 reviews )

Matthew Gumbleton, MD, PhD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 1A, Thoracic
Salt Lake City
801-587-4470

  • Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Patient Rating

    5.0 /5
    ( out of 14 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    June 09, 2024
    HUNTSMAN CANCER CENTER

    The only shortcoming I experienced was that I had, at times, difficulty understanding some of what he was saying due mostly to my very poor hearing

    April 08, 2024
    HUNTSMAN CANCER CENTER

    Dr. Gumbleton is a great Doctor! he cares about me and my family !!

    April 07, 2024
    HUNTSMAN CANCER CENTER

    Dr Gumbelton listened very well, told me what he was thinking, not holding back, and I had an excellent time with him, and I highly recommend him. I'm glad that I am under his care. I could not be more satisfied than I am now.

    March 18, 2024
    HUNTSMAN CANCER CENTER

    Dr Matthew N Gumbleton is one of the greatest doctors I¿ve have seen by through my treatments he is so good in listening to every word you say and always has a answer to your questions or will give you his best advice to any issues you may have I feel so save having him as my doctor

    March 10, 2024
    HUNTSMAN CANCER CENTER

    Dr Gumbleton is caring and compassionate. He goes to great lengths to help you understand what is happening, what treatment options are and letting you make your decisions. Excellent Excellent care.

    February 22, 2024
    HUNTSMAN CANCER CENTER

    I made the best decision in getting a second opinion and switching doctors with Dr. Gumbleton he made me feel so safe and caring as if I was a family and I'm looking forward to fighting this battle of my cancer with Dr. Gumbleton and staff at my side because I have all the confidence we can get through this together.

    January 30, 2024
    HUNTSMAN CANCER CENTER

    Dr. Gumbleton is the best !!

    December 26, 2023
    HUNTSMAN CANCER CENTER

    I feel Dr. Gumbleton is a very knowledgeable professional.

    December 24, 2023
    HUNTSMAN CANCER CENTER

    I love Doctor Gumbleton he listened to all my needs and takes his time with his patients

    See More Patient Comments

  • Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Education history

    Postdoctoral Fellowship Huntsman Cancer Institute Postdoctoral Research Fellow
    Hematology & Medical Oncology - Huntsman Cancer Institute Fellow
    Residency Internal Medicine - University of Utah School of Medicine Resident
    Internal Medicine - University of Utah School of Medicine Intern/Resident
    Professional Medical Microbiology & Immunology - SUNY Upstate Medical University Norton College of Medicine M.D., Ph.D.
    Microbiology & Immunology - Kalamazoo College B.S.

    Selected Publications

    Journal Article

    1. Gumbleton M, Allan S, Conway H, Boucher K, Marvin J, Hawks J, Burnett W, Van Brocklin M, Whisenant J, Gilcrease G, Gupta S (2023). A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC Res Notes, 16(1), 16. (Read full article)
    2. Gumbleton M, Sudan R, Fernandes S, Engelman RW, Russo CM, Chisholm JD, Kerr WG (2017). Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival. Sci Signal, 10(500). (Read full article)
    3. Iyer S, Brooks R, Gumbleton M, Kerr WG (2015). SHIP1-expressing mesenchymal stem cells regulate hematopoietic stem cell homeostasis and lineage commitment during aging. Stem Cells Dev, 24(9), 1073-81. (Read full article)
    4. Gumbleton M, Vivier E, Kerr WG (2015). SHIP1 intrinsically regulates NK cell signaling and education, resulting in tolerance of an MHC class I-mismatched bone marrow graft in mice. J Immunol, 194(6), 2847-54. (Read full article)
    5. Fernandes S, Brooks R, Gumbleton M, Park MY, Russo CM, Howard KT, Chisholm JD, Kerr WG (2015). SHIPi Enhances Autologous and Allogeneic Hematolymphoid Stem Cell Transplantation. EBioMedicine, 2(3), 205-213. (Read full article)
    6. Gumbleton M, Kerr WG (2013). Role of inositol phospholipid signaling in natural killer cell biology. Front Immunol, 4, 47. (Read full article)
    7. Fuhler GM, Brooks R, Toms B, Iyer S, Gengo EA, Park MY, Gumbleton M, Viernes DR, Chisholm JD, Kerr WG (2012). Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Mol Med, 18(1), 65-75. (Read full article)
    8. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman NM, Al-Muhsen S, Galicchio M, Abel L, Picard C, Casanova JL (2011). Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science, 332(6025), 65-8. (Read full article)

    Patent

    1. William K, Gumbleton M (2020). Ship inhibition to induce activation of natural killer cells. U.S. Patent No. WO2015195812. Washington, D.C.:U.S. Patent and Trademark Office.